[Anticoagulation in atrial fibrillation]

Christian Binggeli1, Corinna B Brunckhorst

  • 1HerzKreislaufZentrum, Klinik für Kardiologie, Departement für Innere Medizin, Universitätsspital Zürich, Rämistrasse 100, 8091 Zürich, Schweiz. christian.binggeli@usz.ch

Herz
|February 15, 2008
PubMed

Insights

Atrial fibrillation increases stroke risk in the elderly. Anticoagulation effectively reduces this risk, but requires careful balancing of bleeding risks and lifestyle factors.

Area of Science:

  • Cardiology
  • Geriatrics
  • Pharmacology

Context:

  • Atrial fibrillation is the most prevalent cardiac arrhythmia in older adults.
  • It significantly contributes to morbidity and mortality, primarily through thromboembolic events like stroke.
  • Effective stroke prevention is crucial for managing patients with atrial fibrillation.

Purpose:

  • To review the efficacy and risks of anticoagulation strategies for stroke prevention in atrial fibrillation.
  • To compare the effectiveness of acetylsalicylic acid versus vitamin K antagonists.
  • To highlight the importance of individualized risk assessment for thromboembolism and bleeding.

Summary:

  • Anticoagulation therapy substantially lowers the risk of stroke and death in patients with atrial fibrillation.
  • Vitamin K antagonists demonstrate superior efficacy compared to acetylsalicylic acid in reducing thromboembolic events.
  • The decision to anticoagulate must weigh the benefits of stroke reduction against the increased risk of bleeding and treatment-related burdens.

Impact:

  • Informs clinical decision-making regarding stroke prophylaxis in elderly patients with atrial fibrillation.
  • Emphasizes the need for personalized risk-benefit assessments in anticoagulation therapy.
  • Highlights the trade-offs between anticoagulation efficacy, bleeding risk, and patient lifestyle considerations.

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...